Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Role of Sleep in Protecting Spatial Memories From Age-Related Decline

10 de noviembre de 2026 actualizado por: Eitan Schechtman, University of California, Irvine

Healthy aging is characterized by impaired spatial memory compared to younger adults. These impairments not only negatively impact quality of life but are also an early marker for the onset of dementia, especially Alzheimer's Disease. While sleep plays an active role in spatial memory consolidation in young adults, the extent to which sleep contributes to this process in aged adults is yet to be determined. The objective of this developmental R21 project is to determine the impact of sleep on spatial memory in cognitively healthy, aged adults, and evaluate the potential for a sleep intervention targeting memory reactivation to improve performance in this population. The project will include a single experiment using an ecologically valid ambulatory virtual environment to test the effects of sleep on spatial memory performance in aged adults.

Aim 1 will determine whether post-learning sleep benefits spatial memory in aged adults, more so than a period of wakefulness. Spatial memory performance will be measured using well-established tasks in a virtual environment, before and after a 90-minute delay consisting of either an EEG-monitored nap or wakefulness. Changes in performance between these two conditions will be measured after the 90-minute delay and again one week later. The key hypothesis for this aim is that post-learning sleep will improve spatial memory recall more than an equivalent period of wakefulness, and that this improvement will correlate with sleep stages and EEG waveforms that are linked with memory consolidation.

Aim 2 will test whether targeted memory reactivation, a technique used to bias memory consolidation by obtrusively presenting sounds during sleep, can be used to enhance spatial memory in aged adults. To this end, task-related sounds will be presented to participants during a nap immediately after learning and during nocturnal sleep over the following week. Spatial memory performance will be compared between this group and a sleep group for which no sounds will be presented during sleep. The key hypotheses are that this manipulation will improve spatial memory performance, and that these behavioral effects will be mediated by memory-related EEG waveforms elicited by sounds presented during sleep.

By combining sleep, high-density electrophysiology, and a realistic testing environment, this project will determine the benefit of sleep on spatial memory in aged adults and test ways to leverage sleep to make consolidation more efficient. Results will inform our understanding of sleep-dependent consolidation in aged adults and pave the way for scalable, non-invasive treatments to improve day-to-day life and provide critical protections against dementia.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

126

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Eitan Schechtman-Drayman
  • Número de teléfono: 847-722-9220
  • Correo electrónico: eitans@uci.edu

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion:

  1. Age >=60.
  2. Montreal Cognitive Assessment score above 25.
  3. Good general health with no disease or conditions expected to interfere with the study.
  4. Fluent in English.
  5. Fully ambulatory without the use of a cane, walker, or wheelchair.
  6. Believe they will be able to fall asleep in a lab setting for an afternoon nap.

Exclusion:

  1. No history or current diagnosis of psychiatric disorders.
  2. No history or current neurological disease.
  3. No current sleep disorder, including sleep apnea and insomnia.
  4. No snoring during sleep.
  5. No uncorrected hearing, visual or motor impairment.
  6. No changes in medication usage over the past month and no plans to make such changes over the course of the study.

All inclusion/exclusion criteria, except for the Montreal Cognitive Assessment, will be based on self-report.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Wake group

Participants watch a feature-length film ("Stand By Me") in the study room for 90 minutes. They are instructed to remain awake and alert throughout. The experimenter monitors wakefulness from the control room via a baby monitor and a real-time EEG display. If EEG signs of non-rapid-eye-movement-sleep (NREM) Stage 1 or deeper sleep onset are observed, the participant is prompted to remain awake.

Comparador activo: Sleep group

Participants are given a 90-minute nap opportunity in a darkened sleep room (bed, clean linens, blanket) with low-volume white noise delivered via earphones. EEG (electroencephalography) with EOG (electrooculography) and EMG (electromyography) is recorded continuously. During NREM sleep, auditory cues that are unrelated to the virtual reality (VR) task are delivered. Once the experimenter confirms via real-time EEG that the participant is in NREM Stage 2 or Stage 3 sleep, non-task-associated auditory cues are delivered via a speaker at a volume calibrated individually during a Sound Volume Test before the nap - the lowest volume at which the participant can reliably detect the sound while awake. Following the nap, participants may shower or wash up in a private room with a sink.

This group will be allowed to sleep shortly after learning.

Experimental: Sleep+TargetedMemoryReactivation (TMR) Group

Participants follow the same nap protocol as the Sleep group, except that task-relevant sounds are presented during sleep. A minimum of 6 successful cue presentations during the nap is required for inclusion in TMR-specific analyses.

This group will be allowed to sleep shortly after learning.

The researchers will unobtrusively and repeatedly present a sound that was linked with a spatial task during sleep. This method was shown to improve memory in various tasks. The sounds will be presented both in the lab and at home. In both cases, the sounds will be presented during non-REM sleep stages 2 and 3. The sounds will only be presented to the Sleep+TMR group (N = 42).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Performance on spatial memory task - wayfinding task
Periodo de tiempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Accuracy will be measured (percent of correct trials)

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week
Performance on spatial memory task - pointing task
Periodo de tiempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Angular error will be measured (averaged over trials)

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Performance on other memory tasks - paired-associates task
Periodo de tiempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

The researchers will use the paired-associates task to examine the effects of sleep on declarative memories. Percent correct pairs will be used.

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week
Performance on other memory tasks - serial reaction time task
Periodo de tiempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

The researchers will use the serial reaction time task to examine the effects of sleep on non-declarative memories. The number of correct sequences will be used.

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

5 de noviembre de 2026

Finalización primaria (Estimado)

31 de marzo de 2028

Finalización del estudio (Estimado)

31 de marzo de 2028

Fechas de registro del estudio

Enviado por primera vez

29 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 7502
  • R21AG101676 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All datasets that can be shared will be deposited in OpenNeuro, which is an NIH-supported free and open platform for validating and sharing data. De-identified behavioral data, task programs and code, analysis code, experimental protocols, and any additional metadata will be stored and shared on the Open Science Framework. Additional code will be available on GitHub.

Marco de tiempo para compartir IPD

Shared data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the end of the funding period.

Criterios de acceso compartido de IPD

There are no anticipated factors or limitations that will affect the access, distribution or reuse of the scientific data generated by the proposal.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .